- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05238844
A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection
A Phase 2a Randomized, Double-blinded, Placebo-controlled, Multi Center, Dose Ranging Study of the Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Republic Of Moldova
-
Chisinau, Republic Of Moldova, Moldova, Republic of
- Republican Clinical Hospital "Timofei Mosneaga" Arensia EM Unit
-
-
-
-
-
Kyiv, Ukraine
- Medical Center of Limited Liability Company "Harmoniya Krasy"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form (ICF)
- Stated willingness to comply with all study procedures and availability for the duration of the study
If female, meets one of the following criteria:
Is of childbearing potential and agrees to use an acceptable contraceptive method. Acceptable contraceptive methods include:
- Abstinence from heterosexual intercourse from the first study drug administration through to at least 6 months after the last dose of the study drug or until completion of the study, whichever is longer
- Use a non-hormonal intrauterine device, from at least 28 days prior to the first study drug administration through to at least 6 months after the last dose of the study drug or until completion of the study, whichever is longer, with a male condom or a diaphragm/cervical cap plus spermicide from the first study drug administration through to at least 30 days after the last dose of the study drug or until completion of the study, whichever is longer
- Use of a double-barrier method
- Male partner vasectomized at least 6 months prior to the first study drug administration Or
- Is of non-childbearing potential, defined as surgically sterile (ie, has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a postmenopausal state (ie, at least 1 year without menses without an alternative medical condition prior to the first study drug administration and follicle-stimulating hormone [FSH] levels within the normal ranges for postmenopausal state of the clinical site at screening). If the subject engages in sexual relations, a barrier method (male or female condom) should be used to prevent the spread of HBV.
If male, meets one of the following criteria:
a) Is able to procreate and agrees to use one of the accepted contraceptive regimens and not to donate sperm from the first study drug administration to at least 90 days after the last drug administration. An acceptable method of contraception includes one of the following:
- Abstinence from heterosexual intercourse
- Male condom with spermicide or male condom with a vaginal spermicide (gel, foam, or suppository) Or c) Is unable to procreate; defined as surgically sterile (ie, has undergone a vasectomy at least 6 months prior to the first study drug administration). If the subject engages in sexual relations, a barrier method (male or female condom) should be used to prevent the spread of HBV.
- Male or female aged at least 18 years but not older than 70 years
- Body mass index (BMI) within 18.0 kg/m2 to 35.0 kg/m2, inclusively
- Light-, non- or ex-smoker (A light smoker is defined as someone using 10.0 nicotine units or less per day for at least 90 days prior to the first study drug administration [refer to APPENDIX 7 for conversions of nicotine usage]. An ex-smoker is defined as someone who completely stopped using nicotine products for at least 6 months prior to the first study drug administration)
- Serum HBsAg positive at screening and at least 6 months prior to screening.
- Serum HBeAg positive and HBV DNA ≥ 20,000 IU/mL, or serum HBeAg negative and HBV DNA ≥ 2,000 IU/mL at screening
- ALT and AST < 5 times the upper limit of normal (ULN) at screening and on the day prior to the first study drug administration (Day -1)
Exclusion Criteria:
- Female who is lactating at screening
- Female who is pregnant according to the pregnancy test at screening or prior to the first study drug administration
- History of significant hypersensitivity to clevudine, tenofovir disoproxil fumarate or any related products (including excipients of ATI-2173, tenofovir disoproxil fumarate, and the placebo) as well as severe hypersensitivity reactions (like angioedema) to any drugs
- History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
- Presence of clinically significant muscle disorders, myopathies or other forms of liver disease
- Presence of any clinically significant disease, as captured in the medical history or evidence of findings on the physical examination, vital sign assessment and/or ECG assessment, and that would otherwise exclude subject from eligibility in the context of all other listed inclusion and exclusion criteria, as determined by an Investigator
- Presence of clinically significant ECG abnormalities at the screening visit, as defined by medical judgment
- Positive test result for alcohol and/or drugs of abuse at screening or prior to the first drug administration
- Any history of tuberculosis
- Active illicit drug use including, but not limited to, cocaine, heroin and methamphetamine (the use of cannabinoids is acceptable)
- Significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
- Use of amiodarone in the 28 days prior to the first study drug administration
- Presence or history of clinically significant gastrointestinal or kidney disease, or surgery that may affect drug bioavailability
Cirrhosis of the liver as determined by one of the following:
- A score greater than F2 for liver fibrosis by FibroScan or FibroSure test within 6 months prior to screening or at the time of screening Or
- A score greater than F2 on liver biopsy within 12 months prior to screening or at the time of screening
- History of or known presence of hepatocellular carcinoma
- Acute infection or any other clinically significant illness within 14 days of Day 1 of the study
- History of organ transplantation
- Presence of uncontrolled hypertension
- Positive screening results to HIV Ag/Ab combo or hepatitis C virus tests
- Any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of an Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
- Intake of an Investigational Product (IP) in the 28 days prior to the first study drug administration
- Donation of 50 mL or more of blood in the 28 days prior to the first study drug administration
- Donation of 500 mL or more of blood in the 56 days prior to the first study drug administration
- Previous approved or investigational treatment for HBV, including nucleoside therapy, other than treatment by tenofovir or interferon alpha. Prior treatment with tenofovir or interferon alpha must have been discontinued at least 6 months prior to Screening.
- Positive screening results to hepatitis D virus (HDV) tests
- History of significant hypersensitivity to excipients of vebicorvir or its placebo
- Current or prior use of prohibited concomitant medications as defined in Section 4.5.1.
- Participation in the ANTT201 study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ATI-2173 25mg, Vebicorvir 300mg and Tenofovir 300mg
Subjects randomized to active arm will receive active 25mg ATI-2173 + active Vebicorvir 300mg + active Tenofovir 300mg
|
ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine.
It will be dosed as a capsule by mouth.
Vebicorvir (formerly ABI-H0731) is an orally administered, potent and selective small molecule inhibitor of the HBV core protein
Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
|
ACTIVE_COMPARATOR: Tenofovir Disoproxil Fumarate
Subjects randomized to placebo arm will receive placebo 25mg ATI-2173 + placebo Vebicorvir 300mg + active Tenofovir 300mg
|
Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percentage of subjects who experienced at least 1 treatment-emergent adverse event (TEAE)
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Alanine aminotransferase and aspartate aminotransferase levels versus time
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
The percentage of subjects who experienced at least 1 treatment-emergent serious adverse event (TE SAE)
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
The percentage of subjects who experienced a treatment-emergent dose-limiting toxicity (TE DLT)
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
The percentage of subjects who experienced at least 1 treatment-emergent Division of AIDS (DAIDS) Grade 1, 2, 3, 4, or 5 laboratory abnormality
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
The percentage of subjects who discontinued the study drug due to a TEAE
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Time to HBV viral load relapse in HBV-infected subjects as measured by HBV DNA viral load in IU/mL
Time Frame: Through study completion, an average of 1 year, which is 6 months after end of treatment
|
Through study completion, an average of 1 year, which is 6 months after end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Baseline-adjusted maximal reduction in HBV DNA viral load (Emax,HBV) through 6 months after end of treatment following ATI-2173 + vebicorvir + TDF or placebo + TDF for 90 days in HBV-infected subjects
Time Frame: Through study completion, an average of 1 year, which is 6 months after end of treatment
|
Through study completion, an average of 1 year, which is 6 months after end of treatment
|
TEmax,HBV through 6 months after end of treatment following ATI-2173 + vebicorvir + TDF or placebo + TDF for 90 days in HBV-infected subjects
Time Frame: Through study completion, an average of 1 year, which is 6 months after end of treatment
|
Through study completion, an average of 1 year, which is 6 months after end of treatment
|
AUEC(HBV) through 6 months after end of treatment following ATI-2173 + vebicorvir + TDF or placebo + TDF for 90 days in HBV-infected subjects
Time Frame: Through study completion, an average of 1 year, which is 6 months after end of treatment
|
Through study completion, an average of 1 year, which is 6 months after end of treatment
|
Proportion of subjects with HBV DNA sustained viral response as measured by HBV DNA viral load at 6 months after end of treatment
Time Frame: Through study completion, an average of 1 year, which is 6 months after end of treatment
|
Through study completion, an average of 1 year, which is 6 months after end of treatment
|
Cmax of ATI-2173, clevudine and M1 in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Tmax of ATI-2173, clevudine and M1 in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Ctrough of ATI-2173, clevudine and M1 in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Ctau of ATI-2173, clevudine and M1 in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
AUC0-24 of ATI-2173, clevudine and M1 in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
AUCtau of ATI-2173, clevudine and M1 in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
t1/2 of ATI-2173, clevudine and M1 in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
RAC(Cmax) of ATI-2173, clevudine and M1 in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
RAC(AUC) of ATI-2173, clevudine and M1 in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Proportion of subjects with HBV SVR12, SVR18, and SVR24months
Time Frame: Through study completion, an average of 1 year, or through 24 months if applicable
|
Through study completion, an average of 1 year, or through 24 months if applicable
|
Proportion of subjects with on-treatment ALT flares
Time Frame: Through Day 90
|
Through Day 90
|
Proportion of subjects with off-treatment ALT flares
Time Frame: From Day 90 through end of study, about 6 months
|
From Day 90 through end of study, about 6 months
|
Rate of HBV viral load return to baseline off-treatment
Time Frame: From Day 90 through end of study, about 6 months
|
From Day 90 through end of study, about 6 months
|
Relationship between HBV RNA and HBV Sustained Viral Response at 6 months
Time Frame: Through study completion, an average of 1 year, which is 6 months after treatment
|
Through study completion, an average of 1 year, which is 6 months after treatment
|
Change from baseline value in HBV RNA at end of treatment and Sustained Viral Response at 6 months
Time Frame: Through study completion, an average of 1 year, 6 months after treatment
|
Through study completion, an average of 1 year, 6 months after treatment
|
Change from baseline in HBsAg over time and Sustained Viral Response at 6 months
Time Frame: Through study completion, an average of 1 year, 6 months after treatment
|
Through study completion, an average of 1 year, 6 months after treatment
|
Change from baseline value in HBcrAg at end of treatment and Sustained Viral Response at 6 months
Time Frame: Through study completion, an average of 1 year, 6 months after treatment
|
Through study completion, an average of 1 year, 6 months after treatment
|
Relationship between HBV DNA Sustained Viral Response and HBsAg
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Reduction from baseline in HBsAg following ATI-2173 + vebicorvir + TDF or placebo + TDF for 90 days in HBV-infected subjects
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Reduction from baseline in HBV RNA following ATI-2173 + vebicorvir + TDF or placebo + TDF for 90 days in HBV-infected subjects
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Reduction from baseline in HBcrAg following ATI-2173 + vebicorvir + TDF or placebo + TDF for 90 days in HBV-infected subjects
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Cmax of tenofovir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Tmax of tenofovir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Ctrough of tenofovir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Ctau of tenofovir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
AUC0-24 of tenofovir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
t1/2 of tenofovir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
RAC(Cmax) of tenofovir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
RAC(AUC) of tenofovir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Cmax of vebicorvir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Tmax of vebicorvir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Ctrough of vebicorvir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Ctau of vebicorvir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
AUC0-24 of vebicorvir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
t1/2 of vebicorvir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
RAC(Cmax) of vebicorvir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
RAC(AUC) of vebicorvir in plasma
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Correlation between individual tie to viral load relapse and Day 90 clevudine, vebicorvir, and tenofovir Cmin and AUC
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Correlation between SVR6 and Day 90 clevudine, vebicorvir, and tenofovir Cmin and AUC
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Virus Diseases
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Herpesviridae Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
Other Study ID Numbers
- ANTT202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis b
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
Clinical Trials on ATI-2173 25mg
-
Antios Therapeutics, IncCompletedHepatitis B, ChronicCanada, Moldova, Republic of, Ukraine
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
-
Antios Therapeutics, IncTerminatedHepatitis D | Hepatitis B, ChronicMoldova, Republic of, Ukraine
-
Aclaris Therapeutics, Inc.TerminatedCryopyrin-Associated Periodic SyndromeUnited States
-
Autonomic Technologies, Inc.CompletedHigh Frequency, High Disability MigraineBelgium, Denmark, Spain
-
Autonomic Technologies, Inc.UnknownChronic Cluster HeadacheUnited States
-
ARYx TherapeuticsCompletedAtrial FibrillationUnited States, Canada
-
Aclaris Therapeutics, Inc.CompletedAtopic DermatitisUnited States
-
Antios Therapeutics, IncCompleted
-
Procter and GambleARYx TherapeuticsTerminatedPost Prandial Distress SyndromeUnited States, Canada, United Kingdom